November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
January 2025 in “Regenerative Biomaterials” The cerium-polypeptide hydrogel effectively heals drug-resistant bacterial wounds by fighting bacteria, reducing inflammation, and promoting tissue repair.
13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
July 1994 in “Annals of Pharmacotherapy” Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
Icosapent ethyl may help treat long-lasting symptoms after COVID-19.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
July 2024 in “Reactions Weekly” May 2011 in “Utrecht University Repository (Utrecht University)” The nicotinamide supplement did not reduce symptoms in horses with insect bite hypersensitivity.
June 2024 in “Military Medicine” Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
19 citations
,
February 2023 in “Environmental and experimental botany” Jasmonic acid helps plants grow, defend against threats, and survive stressful conditions like drought and salt.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
3 citations
,
January 2021 in “Therapeutic advances in infectious disease” A 9-year-old girl with a healthy immune system was successfully treated for a severe fungal scalp infection caused by Microsporum audouinii.
1 citations
,
March 2019 in “International Journal of Current Pharmaceutical Research” The essential oils from Hedyotis corymbosa, Inula racemose, and Holostemma adakodien have significant antibacterial and antifungal properties.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
June 2024 in “Plastic & Reconstructive Surgery Global Open” JOLT uses fillers to lift and tighten the lower face and neck.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
July 2024 in “Journal of Investigative Dermatology” Baicalin may help treat severe drug-induced skin reactions.
August 2025 in “Australasian Journal of Dermatology” Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.